COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A06/07/2017
-   
  Targovax ASA: Registration of share capital increase following the private placement06/07/2017
-   
  Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis06/07/2017
-   
  Shire plc : Additional Listing06/07/2017
-   
  MITHRA STRENGTHENS E4 PATENT POSITION IN AUSTRALIAN MARKET06/07/2017
-   
  PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")06/07/2017
-   
  MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test06/07/2017
-   
  MDxHealth lance AssureMDx, un test de biopsie liquide pour la détection du cancer de la vessie06/07/2017
-   
  Le candidat-médicament QRX-411 de ProQR pour le syndrome d'Usher obtient la désignation d'Orphan Drug (médicament orphelin) de la FDA et de l'EMA06/07/2017
-   
  Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis05/07/2017
-   
  ETC's Sterilization Systems Group Awarded Eight Contracts05/07/2017
-   
  Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis05/07/2017
-   
  Half-Year Report on the DBV Technologies Liquidity Contract with Natixis05/07/2017
-   
  Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares05/07/2017
-   
  Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease05/07/2017
-   
  Arques Clinic : FAB Generation: Fabulous at Fifty and Beyond05/07/2017
-   
  Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME05/07/2017
-   
  Essilor : Nombre total de droits de vote et d'actions composant le capital social au 30 juin 201705/07/2017
-   
  Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 201705/07/2017
Pages